{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=193397®isteredInterest=false&min-ddpModified.=2018-10-09T12%3A55%3A03.492Z", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?identifier=193397®isteredInterest=false&min-ddpModified.=2018-10-09T12%3A55%3A03.492Z", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=193397®isteredInterest=false&_metadata=all&min-ddpModified.=2018-10-09T12%3A55%3A03.492Z", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=193397&_page=0®isteredInterest=false&min-ddpModified.=2018-10-09T12%3A55%3A03.492Z", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=193397®isteredInterest=false&min-ddpModified.=2018-10-09T12%3A55%3A03.492Z", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?identifier=193397®isteredInterest=false&min-ddpModified.=2018-10-09T12%3A55%3A03.492Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1652113", "AnsweringBody" : [{"_value" : "Department for Science, Innovation and Technology"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1652113/answer", "answerText" : {"_value" : "

The Government supports the NHS in R&D of advanced therapy medicinal products, including gene therapies, through the Advanced Therapy Treatment Centre network, hosted by the Cell and Gene Therapy Catapult. The Catapult, head-quartered in Stevenage, is at the centre of the third largest cluster of cell and gene therapy companies in the world.<\/p>

<\/p>

Additionally, the Science and Technology Framework, published in March identifies the critical technologies that are crucial to the UK. It also details the steps required to build upon our world class research base to attract investment, grow UK companies and talent, and innovate successfully and safely.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4020", "label" : {"_value" : "Biography information for George Freeman"} } , "answeringMemberConstituency" : {"_value" : "Mid Norfolk"} , "answeringMemberPrinted" : {"_value" : "George Freeman"} , "dateOfAnswer" : {"_value" : "2023-07-21", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2023-07-21T09:49:28.12Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "216"} , "answeringDeptShortName" : {"_value" : "Science, Innovation and Technology"} , "answeringDeptSortName" : {"_value" : "Science, Innovation and Technology"} , "date" : {"_value" : "2023-07-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Technology"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Science, Innovation and Technology, with reference to her speech at the Creating a Scientific Superpower Conference on 28 June 2023, what steps she is taking to help ensure that (a) one-time gene therapies and (b) other revolutionary emerging technologies are available in the UK.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4124", "label" : {"_value" : "Biography information for Chi Onwurah"} } , "tablingMemberConstituency" : {"_value" : "Newcastle upon Tyne Central"} , "tablingMemberPrinted" : [{"_value" : "Chi Onwurah"} ], "uin" : "193397"} , {"_about" : "http://data.parliament.uk/resources/1010641", "AnsweringBody" : [{"_value" : "Department for Exiting the European Union "} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1010641/answer", "answerText" : {"_value" : "

The Government is undertaking a wide range of continuing analysis in support of our EU exit negotiations and preparations. We will ensure that Parliament is presented with appropriate analysis ahead of the vote on the final deal, and in Impact Assessments accompanying legislation, where appropriate.<\/p>

<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/3977", "label" : {"_value" : "Biography information for Chris Heaton-Harris"} } , "answeringMemberConstituency" : {"_value" : "Daventry"} , "answeringMemberPrinted" : {"_value" : "Chris Heaton-Harris"} , "dateOfAnswer" : {"_value" : "2018-11-23", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-23T15:08:30.837Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "203"} , "answeringDeptShortName" : {"_value" : "Exiting the European Union "} , "answeringDeptSortName" : {"_value" : "Exiting the European Union "} , "date" : {"_value" : "2018-11-20", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Industry"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Exiting the European Union, what his assessment is of the potential cost to industry of Articles 40-125 of the draft Withdrawal Agreement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1484", "label" : {"_value" : "Biography information for Helen Goodman"} } , "tablingMemberConstituency" : {"_value" : "Bishop Auckland"} , "tablingMemberPrinted" : [{"_value" : "Helen Goodman"} ], "uin" : "193397"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 2, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }